Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab.

ABSTRACT: Neoantigen immunoediting drives immune checkpoint blockade efficacy, yet the molecular features of neoantigens and how neoantigen immunogenicity shapes treatment response remain poorly understood. To address these questions, 80 patients with non-small cell lung cancer were enrolled in the biomarker cohort of CheckMate 153 (CA209-153), which collected radiographic guided biopsy samples before treatment and during treatment with nivolumab. Early loss of mutations and neoantigens during therapy are both associated with clinical benefit. We examined 1,453 candidate neoantigens, including many of which that had reduced cancer cell fraction after treatment with nivolumab, and identified 196 neopeptides that were recognized by T cells. Mapping these neoantigens to clonal dynamics, evolutionary tr

SUBMITTER: Alban TJ 

PROVIDER: S-EPMC12066197 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature